About
IDD Therapeutics Ltd develops drugs for cancer therapy. The company's main focus is improving the safety and efficacy of existing cancer treatments and protocols. The company's proprietary Intelligent Learning Engine (ILE) helps researchers design targeted small-molecule New Therapeutic Entities (NTEs) for cancer therapy. IDD is developing atargeted, multifunctional Mode of Action (MoA) NTE consisting of a neuro-protective antioxidant moiety. IDD-1040 is a small molecule synthesized in a one-step chemical procedure that has the potential to be safer and more effective than many existing treatments. Additional drug candidates, IDD-1010 and IDD-2010, are currently at the early preclinical stage. IDD Therapeutics operates within the New Generation Technology (NGT) incubator, funded by the Israeli Office of the Chief Scientist and private capital.